Jump Financial LLC Sells 39,078 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Jump Financial LLC lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 95.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,676 shares of the company's stock after selling 39,078 shares during the quarter. Jump Financial LLC's holdings in Neurocrine Biosciences were worth $229,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Golden State Wealth Management LLC bought a new stake in Neurocrine Biosciences during the 4th quarter worth about $25,000. Huntington National Bank grew its stake in shares of Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group increased its holdings in shares of Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. Lindbrook Capital LLC raised its position in Neurocrine Biosciences by 53.5% in the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock worth $51,000 after purchasing an additional 130 shares during the last quarter. Finally, R Squared Ltd bought a new position in Neurocrine Biosciences in the 4th quarter worth approximately $61,000. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded down $0.06 during trading hours on Thursday, reaching $107.63. 506,529 shares of the company's stock were exchanged, compared to its average volume of 1,068,143. The company has a market capitalization of $10.65 billion, a price-to-earnings ratio of 32.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. The company's 50-day moving average is $106.56 and its two-hundred day moving average is $121.96. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has approved a stock repurchase plan on Friday, February 21st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

NBIX has been the subject of several research reports. Deutsche Bank Aktiengesellschaft assumed coverage on Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 target price for the company. Evercore ISI lowered their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. HC Wainwright cut their target price on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 26th. Finally, UBS Group cut their price objective on shares of Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating on the stock in a report on Friday, April 4th. Three investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company's stock. According to MarketBeat.com, Neurocrine Biosciences has an average rating of "Moderate Buy" and an average target price of $160.90.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Julie Cooke sold 1,551 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78. Following the sale, the insider now directly owns 19,544 shares of the company's stock, valued at $2,282,348.32. The trade was a 7.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Kevin Charles Gorman sold 2,707 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the completion of the transaction, the director now owns 517,030 shares of the company's stock, valued at $79,064,227.60. The trade was a 0.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,801 shares of company stock worth $2,834,677. Corporate insiders own 4.30% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.